The 2012 A-List: Investor Spotlight On Novartis, Versant
This article was originally published in Start Up
As part of START-UP’s annual Series A coverage, this year’s spotlight shines on the Novartis Venture Funds, the most active corporate group in biopharma company formation, and Versant Ventures, an unlikely device champion.
You may also be interested in...
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.
New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.